Hepatitis B Surface Antigen

Treatment with xalnesiran, a small interfering RNA molecule, plus an immunomodulator resulted in hepatitis B surface antigen loss among adults with chronic HBV infection, according to a study published in The New England Journal of Medicine.

SAN DIEGO — Treatment with combination tobevibart and elebsiran led to hepatitis B surface antigen loss among 39% of patients with chronic HBV and low baseline HBsAg, which rose to 46% by adding pegylated interferon-alfa, data showed.

SAN DIEGO — Retreatment with nucleos(t)ide analogue therapy for relapse after withdrawal did not affect hepatitis B surface antigen seroclearance among patients with chronic HBV infection, according to a researcher at The Liver Meeting.

Bulevirtide was safe and increased the proportion of patients with undetectable hepatitis D virus RNA among those in both the 2 mg and 10 mg dosage groups, according to data published in The New England Journal of Medicine.

Chronic hepatitis B virus infection was significantly associated with an increased risk for intracerebral hemorrhage but not other types of stroke in Chinese adults, according to data presented at the EASL Congress.

Older age, male sex and increased hepatitis B surface antigen correlated with a higher risk for hepatic flare after nucleos(t)ide analogue withdrawal in patients with chronic HBV, according to data at the EASL Congress.

WASHINGTON — Pegylated interferon alpha potentiated the antiviral activity of VIR-2218 in a small subset of noncirrhotic patients with chronic hepatitis B, according to preliminary data presented at The Liver Meeting.

Hepatitis D, in hepatitis B surface antigen-positive individuals, may remain undiagnosed due to lack of testing, particularly in primary care settings, according to a poster.

The United States Preventive Services Task Force recently published a new statement strengthening its 2014 recommendation to screen for hepatitis B virus in adolescents and adults who are at an increased risk for infection.